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Updated U.S. Public Health Service Guidelines
for the Management of Occupational Exposures
to HBV, HCV, and HIV and Recommendations
for Postexposure Prophylaxis
Summary
This report updates and consolidates all previous U.S. Public Health Service
recommendations for the management of health-care personnel (HCP) who have
occupational exposure to blood and other body fluids that might contain hepatitis
B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
Recommendations for HBV postexposure management include initiation of the
hepatitis B vaccine series to any susceptible, unvaccinated person who sustains
an occupational blood or body fluid exposure. Postexposure prophylaxis (PEP)
with hepatitis B immune globulin (HBIG) and/or hepatitis B vaccine series should
be considered for occupational exposures after evaluation of the hepatitis B
surface antigen status of the source and the vaccination and vaccine-response
status of the exposed person. Guidance is provided to clinicians and exposed HCP
for selecting the appropriate HBV PEP.
Immune globulin and antiviral agents (e.g., interferon with or without ribavirin)
are not recommended for PEP of hepatitis C. For HCV postexposure management,
the HCV status of the source and the exposed person should be determined, and
for HCP exposed to an HCV positive source, follow-up HCV testing should be
performed to determine if infection develops.
Recommendations for HIV PEP include a basic 4-week regimen of two drugs
(zidovudine [ZDV] and lamivudine [3TC]; 3TC and stavudine [d4T]; or didanosine
[ddI] and d4T) for most HIV exposures and an expanded regimen that includes the
addition of a third drug for HIV exposures that pose an increased risk for
transmission. When the source person’s virus is known or suspected to be
resistant to one or more of the drugs considered for the PEP regimen, the selection
of drugs to which the source person’s virus is unlikely to be resistant is
recommended.
In addition, this report outlines several special circumstances (e.g., delayed
exposure report, unknown source person, pregnancy in the exposed person,
resistance of the source virus to antiretroviral agents, or toxicity of the PEP
regimen) when consultation with local experts and/or the National Clinicians’ Post-
Exposure Prophylaxis Hotline ([PEPline] 1-888-448-4911) is advised.
Occupational exposures should be considered urgent medical concerns to
ensure timely postexposure management and administration of HBIG, hepatitis B
vaccine, and/or HIV PEP.
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*This interagency working group comprised representatives of CDC, the Food and Drug
Administration (FDA), the Health Resources and Services Administration, and the National
Institutes of Health. Information included in these recommendations may not represent
FDA approval or approved labeling for the particular product or indications in question.
Specifically, the terms “safe” and “effective” may not be synonymous with the FDA-defined
legal standards for product approval.
INTRODUCTION
Avoiding occupational blood exposures is the primary way to prevent transmission
of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus
(HIV) in health-care settings (1 ). However, hepatitis B immunization and postexposure
management are integral components of a complete program to prevent infection fol-
lowing bloodborne pathogen exposure and are important elements of workplace safety
(2 ).
The U.S. Public Health Service (PHS) has published previous guidelines for the man-
agement of HIV exposures that included considerations for postexposure prophylaxis
(PEP) (3–5 ). Since publication of the 1998 HIV exposure guidelines (5 ), several new
antiretroviral agents have been approved by the Food and Drug Administration (FDA),
and more information is available about the use and safety of HIV PEP (6–11 ). In addition,
questions exist regarding considerations about PEP regimens when the source person’s
virus is known or suspected to be resistant to one or more of the antiretroviral agents
that might be used for PEP. Concern also has arisen about the use of PEP when it is not
warranted. Data indicate that some health-care personnel (HCP) take a full course of HIV
PEP after exposures that do not confer an HIV transmission risk (10,11 ).
In September 1999, a meeting of a PHS interagency working group* and expert
consultants was convened by CDC. The PHS working group decided to issue updated
recommendations for the management of occupational exposure to HIV. In addition, the
report was to include recommendations for the management of occupational HBV and
HCV exposures so that a single document could comprehensively address the manage-
ment of occupational exposures to bloodborne pathogens. This report updates and con-
solidates the previous PHS guidelines and recommendations for occupational HBV, HCV,
and HIV exposure management for HCP. Specific practice recommendations for the
management of occupational bloodborne pathogen exposures are outlined to assist
health-care institutions with the implementation of these PHS guidelines (Appendices A
and B). As relevant information becomes available, updates of these recommendations
will be published. Recommendations for nonoccupational (e.g., sexual, pediatric, and
perinatal) HBV, HCV, and HIV exposures are not addressed in these guidelines and can be
found elsewhere (12–15 ).
Definition of Health-Care Personnel and Exposure
In this report, health-care personnel (HCP) are defined as persons (e.g., employees,
students, contractors, attending clinicians, public-safety workers, or volunteers) whose
activities involve contact with patients or with blood or other body fluids from patients in
a health-care, laboratory, or public-safety setting. The potential exists for blood and body
fluid exposure to other workers, and the same principles of exposure management could
be applied to other settings.
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An exposure that might place HCP at risk for HBV, HCV, or HIV infection is defined as
a percutaneous injury (e.g., a needlestick or cut with a sharp object) or contact of mucous
membrane or nonintact skin (e.g., exposed skin that is chapped, abraded, or afflicted with
dermatitis) with blood, tissue, or other body fluids that are potentially infectious (16,17 ).
In addition to blood and body fluids containing visible blood, semen and vaginal secre-
tions also are considered potentially infectious. Although semen and vaginal secretions
have been implicated in the sexual transmission of HBV, HCV, and HIV, they have not
been implicated in occupational transmission from patients to HCP. The following fluids
also are considered potentially infectious: cerebrospinal fluid, synovial fluid, pleural fluid,
peritoneal fluid, pericardial fluid, and amniotic fluid. The risk for transmission of HBV,
HCV, and HIV infection from these fluids is unknown; the potential risk to HCP from
occupational exposures has not been assessed by epidemiologic studies in health-care
settings. Feces, nasal secretions, saliva, sputum, sweat, tears, urine, and vomitus are not
considered potentially infectious unless they contain blood. The risk for transmission of
HBV, HCV, and HIV infection from these fluids and materials is extremely low.
Any direct contact (i.e., contact without barrier protection) to concentrated virus in a
research laboratory or production facility is considered an exposure that requires clinical
evaluation. For human bites, the clinical evaluation must include the possibility that both
the person bitten and the person who inflicted the bite were exposed to bloodborne
pathogens. Transmission of HBV or HIV infection only rarely has been reported by this
route (18–20 ) (CDC, unpublished data, 1998).
BACKGROUND
This section provides the rationale for the postexposure management and prophy-
laxis recommendations presented in this report. Additional details concerning the risk for
occupational bloodborne pathogen transmission to HCP and management of occupa-
tional bloodborne pathogen exposures are available elsewhere (5,12,13,21-24 ).
Occupational Transmission of HBV
Risk for Occupational Transmission of HBV
HBV infection is a well recognized occupational risk for HCP (25 ). The risk of HBV
infection is primarily related to the degree of contact with blood in the work place and also
to the hepatitis B e antigen (HBeAg) status of the source person. In studies of HCP who
sustained injuries from needles contaminated with blood containing HBV, the risk of
developing clinical hepatitis if the blood was both hepatitis B surface antigen (HBsAg)-
and HBeAg-positive was 22%–31%; the risk of developing serologic evidence of HBV
infection was 37%–62%. By comparison, the risk of developing clinical hepatitis from a
needle contaminated with HBsAg-positive, HBeAg-negative blood was 1%–6%, and the
risk of developing serologic evidence of HBV infection, 23%–37% (26 ).
Although percutaneous injuries are among the most efficient modes of HBV trans-
mission, these exposures probably account for only a minority of HBV infections among
HCP. In several investigations of nosocomial hepatitis B outbreaks, most infected HCP
could not recall an overt percutaneous injury (27,28 ), although in some studies, up to one
third of infected HCP recalled caring for a patient who was HBsAg-positive (29,30 ). In
addition, HBV has been demonstrated to survive in dried blood at room temperature on
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environmental surfaces for at least 1 week (31 ). Thus, HBV infections that occur in HCP
with no history of nonoccupational exposure or occupational percutaneous injury might
have resulted from direct or indirect blood or body fluid exposures that inoculated HBV
into cutaneous scratches, abrasions, burns, other lesions, or on mucosal surfaces (32–
34 ). The potential for HBV transmission through contact with environmental surfaces
has been demonstrated in investigations of HBV outbreaks among patients and staff of
hemodialysis units (35–37 ).
Blood contains the highest HBV titers of all body fluids and is the most important
vehicle of transmission in the health-care setting. HBsAg is also found in several other
body fluids, including breast milk, bile, cerebrospinal fluid, feces, nasopharyngeal
washings, saliva, semen, sweat, and synovial fluid (38 ). However, the concentration of
HBsAg in body fluids can be 100–1000—fold higher than the concentration of infectious
HBV particles. Therefore, most body fluids are not efficient vehicles of transmission
because they contain low quantities of infectious HBV, despite the presence of HBsAg.
In serologic studies conducted in the United States during the 1970s, HCP had a
prevalence of HBV infection approximately 10 times higher than the general population
(39–42 ). Because of the high risk of HBV infection among HCP, routine preexposure
vaccination of HCP against hepatitis B and the use of standard precautions to prevent
exposure to blood and other potentially infectious body fluids have been recommended
since the early 1980s (43 ). Regulations issued by the Occupational Safety and Health
Administration (OSHA) (2 ) have increased compliance with these recommendations.
Since the implementation of these recommendations, a sharp decline has occurred in the
incidence of HBV infection among HCP.
PEP for HBV
Efficacy of PEP for HBV. The effectiveness of hepatitis B immune globulin (HBIG) and/
or hepatitis B vaccine in various postexposure settings has been evaluated by prospec-
tive studies. For perinatal exposure to an HBsAg-, HBeAg-positive mother, a regimen
combining HBIG and initiation of the hepatitis B vaccine series at birth is 85%–95%
effective in preventing HBV infection (44,45 ). Regimens involving either multiple doses
of HBIG alone or the hepatitis B vaccine series alone are 70%–75% effective in prevent-
ing HBV infection (46 ). In the occupational setting, multiple doses of HBIG initiated within
1 week following percutaneous exposure to HBsAg-positive blood provides an estimated
75% protection from HBV infection (47–49 ). Although the postexposure efficacy of the
combination of HBIG and the hepatitis B vaccine series has not been evaluated in the
occupational setting, the increased efficacy of this regimen observed in the perinatal
setting, compared with HBIG alone, is presumed to apply to the occupational setting as
well. In addition, because persons requiring PEP in the occupational setting are generally
at continued risk for HBV exposure, they should receive the hepatitis B vaccine series.
Safety of PEP for HBV. Hepatitis B vaccines have been found to be safe when admin-
istered to infants, children, or adults (12,50 ). Through the year 2000, approximately 100
million persons have received hepatitis B vaccine in the United States. The most com-
mon side effects from hepatitis B vaccination are pain at the injection site and mild to
moderate fever (50–55 ). Studies indicate that these side effects are reported no more
frequently among persons vaccinated than among those receiving placebo (51,52 ).
Approximately 45 reports have been received by the Vaccine Adverse Event Report-
ing System (VAERS) of alopecia (hair loss) in children and adults after administration of
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plasma-derived and recombinant hepatitis B vaccine; four persons sustained hair loss
following vaccination on more than one occasion (56 ). Hair loss was temporary for
approximately two thirds of persons who experienced hair loss. An epidemiologic study
conducted in the Vaccine Safety Datalink found no statistical association between alope-
cia and receipt of hepatitis B vaccine in children (CDC, unpublished data, 1998). A low
rate of anaphylaxis has been observed in vaccine recipients based on reports to VAERS;
the estimated incidence is 1 in 600,000 vaccine doses distributed. Although none of the
persons who developed anaphylaxis died, anaphylactic reactions can be life-threaten-
ing; therefore, further vaccination with hepatitis B vaccine is contraindicated in persons
with a history of anaphylaxis after a previous dose of vaccine.
Hepatitis B immunization programs conducted on a large scale in Taiwan, Alaska, and
New Zealand have observed no association between vaccination and the occurrence of
serious adverse events. Furthermore, in the United States, surveillance of adverse events
following hepatitis B vaccination has demonstrated no association between hepatitis B
vaccine and the occurrence of serious adverse events, including Guillain-Barré syn-
drome, transverse myelitis, multiple sclerosis, optic neuritis, and seizures (57–59 ) (CDC,
unpublished data, 1991). However, several case reports and case series have claimed an
association between hepatitis B vaccination and such syndromes and diseases as mul-
tiple sclerosis, optic neuritis, rheumatoid arthritis, and other autoimmune diseases (57,60–
66 ). Most of these reported adverse events have occurred in adults, and no report has
compared the frequency of the purported vaccine-associated syndrome/disease with
the frequency in an unvaccinated population. In addition, recent case-control studies
have demonstrated no association between hepatitis B vaccination and development or
short-term risk of relapse of multiple sclerosis (67,68 ), and reviews by international
panels of experts have concluded that available data do not demonstrate a causal asso-
ciation between hepatitis B vaccination and demyelinating diseases, including multiple
sclerosis (69 ).
HBIG is prepared from human plasma known to contain a high titer of antibody to
HBsAg (anti-HBs). The plasma from which HBIG is prepared is screened for HBsAg and
antibodies to HIV and HCV. The process used to prepare HBIG inactivates and eliminates
HIV from the final product. Since 1996, the final product has been free of HCV RNA as
determined by the polymerase chain reaction (PCR), and, since 1999, all products avail-
able in the United States have been manufactured by methods that inactivate HCV and
other viruses. No evidence exists that HBV, HCV, or HIV have ever been transmitted by
HBIG commercially available in the United States (70,71 ).
Serious adverse effects from HBIG when administered as recommended have been
rare. Local pain and tenderness at the injection site, urticaria and angioedema might
occur; anaphylactic reactions, although rare, have been reported following the injection
of human immune globulin (IG) preparations (72 ). Persons with a history of anaphylactic
reaction to IG should not receive HBIG.
PEP for HBV During Pregnancy. No apparent risk exists for adverse effects to devel-
oping fetuses when hepatitis B vaccine is administered to pregnant women (CDC, unpub-
lished data, 1990). The vaccine contains noninfectious HBsAg particles and should pose
no risk to the fetus. HBV infection during pregnancy might result in severe disease for the
mother and chronic infection for the newborn. Therefore, neither pregnancy nor lacta-
tion should be considered a contraindication to vaccination of women. HBIG is not con-
traindicated for pregnant or lactating women.
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Occupational Transmission of HCV
Risk for Occupational Transmission of HCV
HCV is not transmitted efficiently through occupational exposures to blood. The aver-
age incidence of anti-HCV seroconversion after accidental percutaneous exposure from
an HCV-positive source is 1.8% (range: 0%–7%) (73–76 ), with one study indicating that
transmission occurred only from hollow-bore needles compared with other sharps (75 ).
Transmission rarely occurs from mucous membrane exposures to blood, and no trans-
mission in HCP has been documented from intact or nonintact skin exposures to blood
(77,78 ). Data are limited on survival of HCV in the environment. In contrast to HBV, the
epidemiologic data for HCV suggest that environmental contamination with blood con-
taining HCV is not a significant risk for transmission in the health-care setting (79,80 ),
with the possible exception of the hemodialysis setting where HCV transmission related
to environmental contamination and poor infection-control practices have been impli-
cated (81–84 ). The risk for transmission from exposure to fluids or tissues other than
HCV-infected blood also has not been quantified but is expected to be low.
Postexposure Management for HCV
In several studies, researchers have attempted to assess the effectiveness of IG
following possible exposure to non-A, non-B hepatitis. These studies have been difficult
to interpret because they lack uniformity in diagnostic criteria and study design, and, in all
but one study, the first dose of IG was administered before potential exposure (48,85,86 ).
In an experiment designed to model HCV transmission by needlestick exposure in the
health-care setting, high anti-HCV titer IG administered to chimpanzees 1 hour after
exposure to HCV-positive blood did not prevent transmission of infection (87 ). In 1994,
the Advisory Committee on Immunization Practices (ACIP) reviewed available data re-
garding the prevention of HCV infection with IG and concluded that using IG as PEP for
hepatitis C was not supported (88 ). This conclusion was based on the following facts:
• No protective antibody response has been identified following HCV infection.
• Previous studies of IG use to prevent posttransfusion non-A, non-B hepatitis might
not be relevant in making recommendations regarding PEP for hepatitis C.
• Experimental studies in chimpanzees with IG containing anti-HCV failed to prevent
transmission of infection after exposure.
No clinical trials have been conducted to assess postexposure use of antiviral agents
(e.g., interferon with or without ribavirin) to prevent HCV infection, and antivirals are not
FDA-approved for this indication. Available data suggest that an established infection
might need to be present before interferon can be an effective treatment. Kinetic studies
suggest that the effect of interferon on chronic HCV infection occurs in two phases.
During the first phase, interferon blocks the production or release of virus from infected
cells. In the second phase, virus is eradicated from the infected cells (89 ); in this later
phase, higher pretreatment alanine aminotransferase (ALT) levels correlate with an
increasing decline in infected cells, and the rapidity of the decline correlates with viral
clearance. In contrast, the effect of antiretrovirals when used for PEP after exposure to
HIV is based on inhibition of HIV DNA synthesis early in the retroviral replicative cycle.
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In the absence of PEP for HCV, recommendations for postexposure management are
intended to achieve early identification of chronic disease and, if present, referral for
evaluation of treatment options. However, a theoretical argument is that intervention
with antivirals when HCV RNA first becomes detectable might prevent the development
of chronic infection. Data from studies conducted outside the United States suggest that
a short course of interferon started early in the course of acute hepatitis C is associated
with a higher rate of resolved infection than that achieved when therapy is begun after
chronic hepatitis C has been well established (90–92 ). These studies used various treat-
ment regimens and included persons with acute disease whose peak ALT levels were
500–1,000 IU/L at the time therapy was initiated (2.6–4 months after exposure).
No studies have evaluated the treatment of acute infection in persons with no evi-
dence of liver disease (i.e., HCV RNA-positive <6 months duration with normal ALT lev-
els); among patients with chronic HCV infection, the efficacy of antivirals has been
demonstrated only among patients who also had evidence of chronic liver disease (i.e.,
abnormal ALT levels). In addition, treatment started early in the course of chronic HCV
infection (i.e., 6 months after onset of infection) might be as effective as treatment started
during acute infection (13 ). Because 15%–25% of patients with acute HCV infection
spontaneously resolve their infection (93 ), treatment of these patients during the acute
phase could expose them unnecessarily to the discomfort and side effects of antiviral
therapy.
Data upon which to base a recommendation for therapy of acute infection are insuf-
ficient because a) no data exist regarding the effect of treating patients with acute infec-
tion who have no evidence of disease, b) treatment started early in the course of chronic
infection might be just as effective and would eliminate the need to treat persons who will
spontaneously resolve their infection, and c) the appropriate regimen is unknown.
Occupational Transmission of HIV
Risk for Occupational Transmission of HIV
In prospective studies of HCP, the average risk of HIV transmission after a percutane-
ous exposure to HIV-infected blood has been estimated to be approximately 0.3% (95%
confidence interval [CI] = 0.2%–0.5%) (94 ) and after a mucous membrane exposure,
approximately 0.09% (95% CI = 0.006%–0.5%) (95 ). Although episodes of HIV transmis-
sion after nonintact skin exposure have been documented (96 ), the average risk for
transmission by this route has not been precisely quantified but is estimated to be less
than the risk for mucous membrane exposures (97 ). The risk for transmission after
exposure to fluids or tissues other than HIV-infected blood also has not been quantified
but is probably considerably lower than for blood exposures (98 ).
As of June 2000, CDC had received voluntary reports of 56 U.S. HCP with docu-
mented HIV seroconversion temporally associated with an occupational HIV exposure.
An additional 138 episodes in HCP are considered possible occupational HIV transmis-
sions. These workers had a history of occupational exposure to blood, other infectious
body fluids, or laboratory solutions containing HIV, and no other risk for HIV infection was
identified, but HIV seroconversion after a specific exposure was not documented (99 ).
Epidemiologic and laboratory studies suggest that several factors might affect the
risk of HIV transmission after an occupational exposure. In a retrospective case-control
study of HCP who had percutaneous exposure to HIV, the risk for HIV infection was found
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to be increased with exposure to a larger quantity of blood from the source person as
indicated by a) a device visibly contaminated with the patient’s blood, b) a procedure that
involved a needle being placed directly in a vein or artery, or c) a deep injury (100 ). The
risk also was increased for exposure to blood from source persons with terminal illness,
possibly reflecting either the higher titer of HIV in blood late in the course of AIDS or other
factors (e.g., the presence of syncytia-inducing strains of HIV). A laboratory study that
demonstrated that more blood is transferred by deeper injuries and hollow-bore needles
lends further support for the observed variation in risk related to blood quantity (101 ).
The use of source person viral load as a surrogate measure of viral titer for assessing
transmission risk has not yet been established. Plasma viral load (e.g., HIV RNA) reflects
only the level of cell-free virus in the peripheral blood; latently infected cells might trans-
mit infection in the absence of viremia. Although a lower viral load (e.g., <1,500 RNA
copies/mL) or one that is below the limits of detection probably indicates a lower titer
exposure, it does not rule out the possibility of transmission.
Some evidence exists regarding host defenses possibly influencing the risk for HIV
infection. A study of HIV-exposed but uninfected HCP demonstrated an HIV-specific cyto-
toxic T-lymphocyte (CTL) response when peripheral blood mononuclear cells were stimu-
lated in vitro with HIV-specific antigens (102 ). Similar CTL responses have been observed
in other groups who experienced repeated HIV exposure without resulting infection
(103–108 ). Among several possible explanations for this observation is that the host
immune response sometimes might prevent establishment of HIV infection after a per-
cutaneous exposure; another is that the CTL response simply might be a marker for
exposure. In a study of 20 HCP with occupational exposure to HIV, a comparison was
made of HCP treated with zidovudine (ZDV) PEP and those not treated. The findings from
this study suggest that ZDV blunted the HIV-specific CTL response and that PEP might
inhibit early HIV replication (109 ).
Rationale for HIV PEP
Considerations that influence the rationale and recommendations for PEP include
• the pathogenesis of HIV infection, particularly the time course of early infection;
• the biological plausibility that infection can be prevented or ameliorated by using
antiretroviral drugs;
• direct or indirect evidence of the efficacy of specific agents used for prophylaxis;
and
• the risk and benefit of PEP to exposed HCP.
The following discussion considers each of these concerns.
Role of Pathogenesis in Considering Antiretroviral Prophylaxis. Information about
primary HIV infection indicates that systemic infection does not occur immediately, leav-
ing a brief window of opportunity during which postexposure antiretroviral intervention
might modify or prevent viral replication. In a primate model of simian immunodeficiency
virus (SIV) infection, infection of dendritic-like cells occurred at the site of inoculation
during the first 24 hours following mucosal exposure to cell-free virus. Over the subse-
quent 24–48 hours, migration of these cells to regional lymph nodes occurred, and virus
was detectable in the peripheral blood within 5 days (110 ). Theoretically, initiation of
antiretroviral PEP soon after exposure might prevent or inhibit systemic infection by
limiting the proliferation of virus in the initial target cells or lymph nodes.
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Efficacy of Antiretrovirals for PEP in Animal Studies. Data from animal studies have
been difficult to interpret, in part, because of problems identifying an animal model that
is comparable to humans. In early studies, differences in controlled variables (e.g., choice
of viral strain [based on the animal model used], inoculum size, route of inoculation, time
of prophylaxis initiation, and drug regimen) made extrapolation of the results to humans
difficult. Recently, refinements in methodology have facilitated more relevant studies; in
particular, the viral inocula used in animal studies have been reduced to levels more
analogous to human exposures but sufficient to cause infection in control animals (111–
113 ). These studies provide encouraging evidence of postexposure chemoprophylactic
efficacy.
Studies among primates and in murine and feline animal models have demonstrated
that larger viral inocula decrease prophylactic efficacy (114–117 ). In addition, delaying
initiation, shortening the duration, or decreasing the antiretroviral dose of PEP, individu-
ally or in combination, decreased prophylactic efficacy (113,118–124 ). For example,
when (R)-9-(2-phosphonylmethoxypropyl) adenine (tenofovir) was administered 48 hours
before, 4 hours after, or 24 hours after intravenous SIV inoculation to long-tailed
macaques, a 4-week regimen prevented infection in all treated animals (122 ). A subse-
quent study confirmed the efficacy of tenofovir PEP when administered 24 hours after
intravenous inoculation of a dose of SIV that uniformly results in infection in untreated
macaques. In the same study, protection was incomplete if the tenofovir administration
was delayed to 48 or 72 hours postexposure or if the total duration of treatment was
curtailed to 3 or 10 days (123 ).
Efficacy of Antiretrovirals for PEP in Human Studies. Little information exists from
which the efficacy of PEP in humans can be assessed. Seroconversion is infrequent
following an occupational exposure to HIV-infected blood; therefore, several thousands
of exposed HCP would need to enroll in a prospective trial to achieve the statistical power
necessary to directly demonstrate PEP efficacy (125 ).
In the retrospective case-control study of HCP, after controlling for other risk factors
for HIV transmission, use of ZDV as PEP was associated with a reduction in the risk of HIV
infection by approximately 81% (95% CI = 43%–94%) (100 ). Although the results of this
study suggest PEP efficacy, its limitations include the small number of cases studied and
the use of cases and controls from different cohorts.
In a multicenter trial in which ZDV was administered to HIV-infected pregnant women
and their infants, the administration of ZDV during pregnancy, labor, and delivery and to
the infant reduced transmission by 67% (126 ). Only part of the protective effect of ZDV
was explained by reduction of the HIV viral load in the maternal blood, suggesting that
ZDV prophylaxis, in part, involves a mechanism other than the reduction of maternal
viral burden (127,128 ). Since 1998, studies have highlighted the importance of PEP for
prevention of perinatal HIV transmission. In Africa, the use of ZDV in combination with
lamivudine (3TC) decreased perinatal HIV transmission by 50% when administered dur-
ing pregnancy, labor, and for 1 week postpartum, and by 37% when started at the onset
of labor and continued for 1 week postpartum (129 ). Studies in the United States and
Uganda also have demonstrated that rates of perinatal HIV transmission have been
reduced with the use of abbreviated PEP regimens started intrapartum or during the first
48–72 hours of life (130–132 ).
The limitations of all of these studies with animals and humans must be considered
when reviewing evidence of PEP efficacy. The extent to which data from animal studies
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can be extrapolated to humans is largely unknown, and the exposure route for mother-
to-infant HIV transmission is not similar to occupational exposures; therefore, these
findings might not be directly applicable to PEP in HCP.
Reports of Failure of PEP. Failure of PEP to prevent HIV infection in HCP has been
reported in at least 21 instances (78,133–139 ). In 16 of the cases, ZDV was used alone as
a single agent; in two cases, ZDV and didanosine (ddI) were used in combination
(133,138 ); and in three cases, >3 drugs were used for PEP (137–139 ). Thirteen of the
source persons were known to have been treated with antiretroviral therapy before the
exposure. Antiretroviral resistance testing of the virus from the source person was
performed in seven instances, and in four, the HIV infection transmitted was found to
have decreased sensitivity to ZDV and/or other drugs used for PEP. In addition to possible
exposure to an antiretroviral-resistant strain of HIV, other factors that might have con-
tributed to these apparent failures might include a high titer and/or large inoculum expo-
sure, delayed initiation and/or short duration of PEP, and possible factors related to the
host (e.g., cellular immune system responsiveness) and/or to the source person’s virus
(e.g., presence of syncytia-forming strains) (133 ). Details regarding the cases of PEP
failure involving combinations of antiretroviral agents are included in this report (Table 1).
Antiretroviral Agents for PEP
Antiretroviral agents from three classes of drugs are available for the treatment of
HIV infection. These agents include the nucleoside reverse transcriptase inhibitors
(NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibi-
tors (PIs). Only antiretroviral agents that have been approved by FDA for treatment of
HIV infection are discussed in these guidelines.
Determining which agents and how many to use or when to alter a PEP regimen is
largely empiric. Guidelines for the treatment of HIV infection, a condition usually involv-
ing a high total body burden of HIV, include recommendations for the use of three drugs
(140 ); however, the applicability of these recommendations to PEP remains unknown. In
HIV-infected patients, combination regimens have proved superior to monotherapy regi-
mens in reducing HIV viral load, reducing the incidence of opportunistic infections and
death, and delaying onset of drug resistance (141,142 ). A combination of drugs with
activity at different stages in the viral replication cycle (e.g., nucleoside analogues with a
PI) theoretically could offer an additional preventive effect in PEP, particularly for occupa-
tional exposures that pose an increased risk of transmission. Although the use of a three-
drug regimen might be justified for exposures that pose an increased risk of transmission,
whether the potential added toxicity of a third drug is justified for lower-risk exposures is
uncertain. Therefore, the recommendations at the end of this document provide guid-
ance for two- and three-drug PEP regimens that are based on the level of risk for HIV
transmission represented by the exposure.
NRTI combinations that can be considered for PEP include ZDV and 3TC, 3TC and
stavudine (d4T), and ddI and d4T. In previous PHS guidelines, a combination of ZDV and
3TC was considered the first choice for PEP regimens (3 ). Because ZDV and 3TC are
available in a combination formulation (Combivir™, manufactured by Glaxo Wellcome,
Inc., Research Triangle Park, NC), the use of this combination might be more convenient
for HCP. However, recent data suggest that mutations associated with ZDV and 3TC
resistance might be common in some areas (143 ). Thus, individual clinicians might pre-
fer other NRTIs or combinations based on local knowledge and experience in treating HIV
infection and disease.
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TABLE 1. Reported instances of failure of combination drug postexposure prophylaxis
to prevent HIV infection in health-care personnel exposed to HIV-infected blood
Days to
Hours onset of Source
Report Source to first retroviral Days to patient on
no. of injury Regimen* dose illness  seroconversions† antiretrovirals
1§ Biopsy needle ZDV, ddI 0.50 23 23 yes
2¶ Hollow needle ZDV, ddI** 1.50 45 97 no
3¶ Large-bore
hollow needle 3-drugs†† 1.50 40 55 yes§§
4¶¶ Hollow needle ZDV, 3TC 0.67 70 83 yes***
ddI, IDV
5††† Unknown sharp ddI, d4T 2.00 42 100 yes***
NVP§§§
* ZDV = zidovudine, ddl = didanosine, 3TC = lamivudine, IDV = indinavir, d4T = stavudine,
and NVP = nevirapine
† By enzyme immunoassay for HIV-1 antibody and Western blot.
§ Jochimsen EM. Failures of zidovudine postexposure prophylaxis. Am J Med
1997;102(suppl 5B):52–5.
¶ Lot F, Abiteboul D. Occupational HIV infection in France [Abstract WP-25]. In: Keynote
addresses and abstracts of the 4th ICOH International Conference on Occupational Health
for Health Care Workers. Montreal, Canada, 1999.
** Report 2: ZDV and ddI taken for 48 hours then changed to ZDV alone.
†† Report 3: ZDV, 3TC, and IDV taken for 48 hours then changed to d4T, 3TC, and IDV.
§§ HIV isolate tested and determined to be sensitive to antiretroviral agent(s).
¶¶ Perdue B, Wolderufael D, Mellors J, Quinn T, Margolick J. HIV-1 transmission by a
needlestick injury despite rapid initiation of four-drug postexposure prophylaxis [Ab-
stract 210]. In: Program and abstracts of the 6th Conference on Retroviruses and Oppor-
tunistic Infections. Chicago, IL: Foundation for Retrovirology and Human Health in scien-
tific collaboration with the National Institute of Allergy and Infectious Diseases and CDC,
1999:107.
*** HIV isolate tested and determined to be resistant to antiretroviral agent(s).
††† Beltrami EM, Luo C-C, Dela Torre N, Cardo DM. HIV transmission after an occupational
exposure despite postexposure prophylaxis with a combination drug regimen [Abstract
P-S2-62]. In: Program and abstracts of the 4th Decennial International Conference on
Nosocomial and Healthcare-Associated Infections in conjunction with the 10th Annual
Meeting of SHEA. Atlanta, GA: CDC, 2000:125–6.
§§§ Report 5: ZDV and 3TC taken for one dose then changed to ddI, d4T, and NVP; ddI was
discontinued after 3 days because of severe vomiting.
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The addition of a third drug for PEP following high-risk exposures is based on demon-
strated effectiveness in reducing viral burden in HIV-infected persons. Previously,
indinavir (IDV) or nelfinavir (NFV) were recommended as first-choice agents for inclusion
in an expanded PEP regimen (5 ). Since the publication of the 1998 PEP guidelines,
efavirenz (EFV), an NNRTI; abacavir (ABC), a potent NRTI; and Kaletra™, a PI, have been
approved by FDA. Although side effects might be common with the NNRTIs, EFV might
be considered for expanded PEP regimens, especially when resistance to PIs in the
source person’s virus is known or suspected. ABC has been associated with dangerous
hypersensitivity reactions but, with careful monitoring, may be considered as a third
drug for PEP. Kaletra, a combination of lopinavir and ritonavir, is a potent HIV inhibitor
that, with expert consultation, may be considered in an expanded PEP regimen.
Toxicity and Drug Interactions of Antiretroviral Agents. When administering PEP, an
important goal is completion of a 4-week PEP regimen when PEP is indicated. Therefore,
the toxicity profile of antiretroviral agents, including the frequency, severity, duration,
and reversibility of side effects, is a relevant consideration. All of the antiretroviral agents
have been associated with side effects (Table 2). However, studies of adverse events
have been conducted primarily with persons who have advanced disease (and longer
treatment courses) and who therefore might not reflect the experience in persons who
are uninfected (144 ).
Several primary side effects are associated with antiretroviral agents (Table 2). Side
effects associated with many of the NRTIs are chiefly gastrointestinal (e.g., nausea or
diarrhea); however, ddI has been associated with cases of fatal and nonfatal pancreatitis
among HIV-infected patients treated for >4 weeks. The use of PIs has been associated
with new onset diabetes mellitus, hyperglycemia, diabetic ketoacidosis, exacerbation of
preexisting diabetes mellitus, and dyslipidemia (145–147 ). Nephrolithiasis has been as-
sociated with IDV use; however, the incidence of this potential complication might be
limited by drinking at least 48 ounces (1.5 L) of fluid per 24-hour period (e.g., six 8- ounce
glasses of water throughout the day) (148 ). NFV has been associated with the develop-
ment of diarrhea; however, this side effect might respond to treatment with antimotility
agents that can be prescribed for use, if necessary, at the time the drug is recommended
for PEP. The NNRTIs have been associated with severe skin reactions, including life-
threatening cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Hepa-
totoxicity, including fatal hepatic necrosis, has occurred in patients treated with
nevirapine (NVP); some episodes began during the first few weeks of therapy (FDA,
unpublished data, 2000). EFV has been associated with central nervous system side
effects, including dizziness, somnolence, insomnia, and abnormal dreaming.
All of the approved antiretroviral agents might have potentially serious drug interac-
tions when used with certain other drugs (Appendix C). Careful evaluation of concomi-
tant medications used by an exposed person is required before PEP is prescribed, and
close monitoring for toxicity is also needed. Further information about potential drug
interactions can be found in the manufacturer’s package insert.
Toxicity Associated with PEP. Information from the National Surveillance System
for Health Care Workers (NaSH) and the HIV Postexposure Registry indicates that nearly
50% of HCP experience adverse symptoms (e.g., nausea, malaise, headache, anorexia,
and headache) while taking PEP and that approximately 33% stop taking PEP because of
adverse signs and symptoms (6,7,10,11 ). Some studies have demonstrated that side
effects and discontinuation of PEP are more common among HCP taking three-drug
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TABLE 2. Primary side effects associated with antiretroviral agents
Antiretroviral class/agent Primary side effects and toxicities
Nucleoside reverse transcriptase
inhibitors (NRTIs)
Zidovudine (Retrovir™; ZDV; AZT) anemia, neutropenia, nausea, headache, insomnia,
muscle pain, and weakness
Lamivudine (Epivir™; 3TC) abdominal pain, nausea, diarrhea, rash, and
pancreatitis
Stavudine (Zerit™; d4T) peripheral neuropathy, headache, diarrhea, nausea,
insomnia, anorexia, pancreatitis, increased liver
function tests (LFTs), anemia, and neutropenia
Didanosine (Videx™; ddI) pancreatitis, lactic acidosis, neuropathy, diarrhea,
abdominal pain, and nausea
Abacavir (Ziagen™; ABC) nausea, diarrhea, anorexia, abdominal pain, fatigue,
headache, insomnia, and hypersensitivity reactions
Nonnucleoside reverse transcriptase
inhibitors (NNRTIs)
Nevirapine (Viramune™; NVP) rash (including cases of Stevens-Johnson
syndrome), fever, nausea, headache, hepatitis,
and increased LFTs
Delavirdine (Rescriptor™; DLV) rash (including cases of Stevens-Johnson
syndrome), nausea, diarrhea, headache, fatigue,
and increased LFTs
Efavirenz (Sustiva™; EFV) rash (including cases of Stevens-Johnson
syndrome), insomnia, somnolence, dizziness,
trouble concentrating, and abnormal dreaming
Protease inhibitors (PIs)
Indinavir (Crixivan™; IDV) nausea, abdominal pain, nephrolithiasis, and
indirect hyperbilirubinemia
Nelfinavir (Viracept™; NFV) diarrhea, nausea, abdominal pain, weakness,
and rash
Ritonavir (Norvir™; RTV) weakness, diarrhea, nausea, circumoral paresthesia,
taste alteration, and increased cholesterol and
triglycerides
Saquinavir (Fortovase™; SQV) diarrhea, abdominal pain, nausea, hyperglycemia,
and increased LFTs
Amprenavir (Agenerase™; AMP) nausea, diarrhea, rash, circumoral paresthesia, taste
alteration, and depression
Lopinavir/Ritonavir (Kaletra™) diarrhea, fatigue, headache, nausea, and increased
cholesterol and triglycerides
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combination regimens for PEP compared with HCP taking two-drug combination regi-
mens (7,10 ). Although similar rates of side effects were observed among persons who
took PEP after sexual or drug use exposures to HIV in the San Francisco Post-Exposure
Prevention Project, 80% completed 4 weeks of therapy (149 ). Participants in the San
Francisco Project were followed at 1, 2, 4, 26, and 52 weeks postexposure and received
medication adherence counseling; most participants took only two drugs for PEP.
Serious side effects, including nephrolithiasis, hepatitis, and pancytopenia have been
reported with the use of combination drugs for PEP (6,7,150,151 ). One case of NVP-
associated fulminant liver failure requiring liver transplantation and one case of hyper-
sensitivity syndrome have been reported in HCP taking NVP for HIV PEP (152 ). Including
these two cases, from March 1997 through September 2000, FDA received reports of 22
cases of serious adverse events related to NVP taken for PEP (153 ). These events in-
cluded 12 cases of hepatotoxicity, 14 cases of skin reaction (including one documented
and two possible cases of Stevens-Johnson syndrome), and one case of rhabdomyolysis;
four cases involved both hepatotoxicty and skin reaction, and one case involved both
rhabdomyolysis and skin reaction.
Resistance to Antiretroviral Agents. Known or suspected resistance of the source
virus to antiretroviral agents, particularly to agents that might be included in a PEP
regimen, is a concern for persons making decisions about PEP. Resistance to HIV infection
occurs with all of the available antiretroviral agents, and cross-resistance within drug
classes is frequent (154 ). Recent studies have demonstrated an emergence of drug-
resistant HIV among source persons for occupational exposures (143,155 ). A study
conducted at seven U.S. sites during 1998–1999 found that 16 (39%) of 41 source per-
sons whose virus was sequenced had primary genetic mutations associated with resis-
tance to RTIs, and 4 (10%) had primary mutations associated with resistance to PIs (143 ).
In addition, occupational transmission of resistant HIV strains, despite PEP with combina-
tion drug regimens, has been reported (137,139 ). In one case, a hospital worker became
infected after an HIV exposure despite a PEP regimen that included ddI, d4T, and NVP
(139 ). The transmitted HIV contained two primary genetic mutations associated with
resistance to NNRTIs (the source person was taking EFV at the time of the exposure).
Despite recent studies and case reports, the relevance of exposure to a resistant virus is
still not well understood.
Empiric decisions about the presence of antiretroviral drug resistance are often diffi-
cult to make because patients generally take more than one antiretroviral agent. Resis-
tance should be suspected in source persons when they are experiencing clinical
progression of disease or a persistently increasing viral load, and/or decline in CD4 T-cell
count, despite therapy or a lack of virologic response to therapy. However, resistance
testing of the source virus at the time of an exposure is not practical because the results
will not be available in time to influence the choice of the initial PEP regimen. Further-
more, in this situation, whether modification of the PEP regimen is necessary or will
influence the outcome of an occupational exposure is unknown. No data exist to suggest
that modification of a PEP regimen after receiving results from resistance testing (usually
a minimum of 1–2 weeks) improves efficacy of PEP.
Antiretroviral Drugs During Pregnancy. Data are limited on the potential effects
of antiretroviral drugs on the developing fetus or neonate (156 ). Carcinogenicity and/or
mutagenicity is evident in several in vitro screening tests for ZDV and all other FDA-
licensed NRTIs. The relevance of animal data to humans is unknown; however, because
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teratogenic effects were observed in primates at drug exposures similar to those repre-
senting human therapeutic exposure, the use of EFV should be avoided in pregnant
women (140 ). IDV is associated with infrequent side effects in adults (i.e., hyperbiliru-
binemia and renal stones) that could be problematic for a newborn. Because the half-life
of IDV in adults is short, these concerns might be relevant only if the drug is administered
shortly before delivery.
In a recent study in France of perinatal HIV transmission, two cases of progressive
neurologic disease and death were reported in uninfected infants exposed to ZDV and
3TC (157 ). Laboratory studies of these children suggested mitochondrial dysfunction. In
a careful review of deaths in children followed in U.S. perinatal HIV cohorts, no deaths
attributable to mitochondrial disease have been found (158 ).
Recent reports of fatal and nonfatal lactic acidosis in pregnant women treated through-
out gestation with a combination of d4T and ddI have prompted warnings about use of
these drugs during pregnancy (159 ). Although the case-patients were HIV-infected
women taking the drugs for >4 weeks, pregnant women and their providers should be
advised to consider d4T and ddI only when the benefits of their use outweigh the risks.
PEP Use in Hospitals in the United States. Analysis of data from NaSH provides
information on the use of PEP following occupational exposures in 47 hospitals in the
United States. A total of 11,784 exposures to blood and body fluids was reported from
June 1996 through November 2000 (CDC, unpublished data, 2001). For all exposures
with known sources, 6% were to HIV-positive sources, 74% to HIV-negative sources, and
20% to sources with an unknown HIV status. Sixty-three percent of HCP exposed to a
known HIV-positive source started PEP, and 54% of HCP took it for at least 20 days,
whereas 14% of HCP exposed to a source person subsequently found to be HIV-negative
initiated PEP, and 3% of those took it for at least 20 days. Information recorded about HIV
exposures in NaSH indicates that 46% of exposures involving an HIV-positive source
warranted only a two-drug PEP regimen (i.e., the exposure was to mucous membranes
or skin or was a superficial percutaneous injury and the source person did not have end-
stage AIDS or acute HIV illness); however, 53% of these exposed HCP took >3 drugs
(CDC, unpublished data, 2000). Similarly, the National Clinicians’ Post-Exposure Prophy-
laxis Hotline (PEPline) reported that PEPline staff recommended stopping or not starting
PEP for approximately one half of the HCP who consulted them about exposures
(D. Bangsberg, San Francisco General Hospital, unpublished data, September 1999). The
observation that some HCP exposed to HIV-negative source persons take PEP from
several days to weeks following their exposures suggests that strategies be employed
such as the use of a rapid HIV antibody assay, which could minimize exposure to unnec-
essary PEP (11 ). A recent study demonstrated that use of a rapid HIV test for evaluation
of source persons after occupational exposures not only resulted in decreased use of
PEP, but also was cost-effective compared with use of the standard enzyme immunoas-
say (EIA) test for source persons subsequently found to be HIV-negative (160 ).
RECOMMENDATIONS FOR THE MANAGEMENT OF HCP
POTENTIALLY EXPOSED TO HBV, HCV, or HIV
Exposure prevention remains the primary strategy for reducing occupational
bloodborne pathogen infections; however, occupational exposures will continue to occur.
Health-care organizations should make available to their personnel a system that in-
cludes written protocols for prompt reporting, evaluation, counseling, treatment, and
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follow-up of occupational exposures that might place HCP at risk for acquiring a
bloodborne infection. HCP should be educated concerning the risk for and prevention of
bloodborne infections, including the need to be vaccinated against hepatitis B (17,21,161–
163 ). Employers are required to establish exposure-control plans that include
postexposure follow-up for their employees and to comply with incident reporting
requirements mandated by the 1992 OSHA bloodborne pathogen standard (2 ). Access
to clinicians who can provide postexposure care should be available during all working
hours, including nights and weekends. HBIG, hepatitis B vaccine, and antiretroviral agents
for HIV PEP should be available for timely administration (i.e., either by providing access
on-site or by creating linkages with other facilities or providers to make them available
off-site). Persons responsible for providing postexposure management should be famil-
iar with evaluation and treatment protocols and the facility’s plans for accessing HBIG,
hepatitis B vaccine, and antiretroviral drugs for HIV PEP.
HCP should be educated to report occupational exposures immediately after they
occur, particularly because HBIG, hepatitis B vaccine, and HIV PEP are most likely to be
effective if administered as soon after the exposure as possible. HCP who are at risk for
occupational exposure to bloodborne pathogens should be familiarized with the prin-
ciples of postexposure management as part of job orientation and ongoing job training.
Hepatitis B Vaccination
Any person who performs tasks involving contact with blood, blood-contaminated
body fluids, other body fluids, or sharps should be vaccinated against hepatitis B (2,21 ).
Prevaccination serologic screening for previous infection is not indicated for persons
being vaccinated because of occupational risk, unless the hospital or health-care organi-
zation considers screening cost-effective.
Hepatitis B vaccine should always be administered by the intramuscular route in the
deltoid muscle with a needle 1–1.5 inches long. Hepatitis B vaccine can be administered
at the same time as other vaccines with no interference with antibody response to the
other vaccines (164 ). If the vaccination series is interrupted after the first dose, the
second dose should be administered as soon as possible. The second and third doses
should be separated by an interval of at least 2 months. If only the third dose is delayed,
it should be administered when convenient. HCP who have contact with patients or blood
and are at ongoing risk for percutaneous injuries should be tested 1–2 months after
completion of the 3-dose vaccination series for anti-HBs (21 ). Persons who do not re-
spond to the primary vaccine series (i.e., anti-HBs <10 mIU/mL) should complete a sec-
ond 3-dose vaccine series or be evaluated to determine if they are HBsAg-positive.
Revaccinated persons should be retested at the completion of the second vaccine series.
Persons who do not respond to an initial 3-dose vaccine series have a 30%–50% chance
of responding to a second 3-dose series (165 ). Persons who prove to be HBsAg-positive
should be counseled regarding how to prevent HBV transmission to others and regard-
ing the need for medical evaluation (12,163,166 ). Nonresponders to vaccination who are
HBsAg-negative should be considered susceptible to HBV infection and should be coun-
seled regarding precautions to prevent HBV infection and the need to obtain HBIG pro-
phylaxis for any known or probable parenteral exposure to HBsAg-positive blood.
Booster doses of hepatitis B vaccine are not necessary, and periodic serologic testing to
monitor antibody concentrations after completion of the vaccine series is not recom-
mended. Any blood or body fluid exposure sustained by an unvaccinated, susceptible
person should lead to the initiation of the hepatitis B vaccine series.
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Treatment of an Exposure Site
Wounds and skin sites that have been in contact with blood or body fluids should be
washed with soap and water; mucous membranes should be flushed with water. No
evidence exists that using antiseptics for wound care or expressing fluid by squeezing
the wound further reduces the risk of bloodborne pathogen transmission; however, the
use of antiseptics is not contraindicated. The application of caustic agents (e.g., bleach) or
the injection of antiseptics or disinfectants into the wound is not recommended.
Exposure Report
If an occupational exposure occurs, the circumstances and postexposure manage-
ment should be recorded in the exposed person’s confidential medical record (usually on
a form the facility designates for this purpose) (Box 1). In addition, employers should
follow all federal (including OSHA) and state requirements for recording and reporting
occupational injuries and exposures.
BOX 1. Recommendations for the contents of the occupational exposure report
• date and time of exposure;
• details of the procedure being performed, including where and how the
exposure occurred; if related to a sharp device, the type and brand of
device and how and when in the course of handling the device the
exposure occurred;
• details of the exposure, including the type and amount of fluid or material
and the severity of the exposure (e.g., for a percutaneous exposure, depth
of injury and whether fluid was injected; for a skin or mucous membrane
exposure, the estimated volume of material and the condition of the skin
[e.g., chapped, abraded, intact]);
• details about the exposure source (e.g., whether the source material
contained HBV, HCV, or HIV; if the source is HIV-infected, the stage of
disease, history of antiretroviral therapy, viral load, and antiretroviral
resistance information, if known);
• details about the exposed person (e.g., hepatitis B vaccination and
vaccine-response status); and
• details about counseling, postexposure management, and follow-up.
Evaluation of the Exposure and the Exposure Source
Evaluation of the Exposure
The exposure should be evaluated for the potential to transmit HBV, HCV, and HIV
based on the type of body substance involved and the route and severity of the exposure
(Box 2). Blood, fluid containing visible blood, or other potentially infectious fluid (including
semen; vaginal secretions; and cerebrospinal, synovial, pleural, peritoneal, pericardial,
and amniotic fluids) or tissue can be infectious for bloodborne viruses. Exposures to
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these fluids or tissue through a percutaneous injury (i.e., needlestick or other penetrating
sharps-related event) or through contact with a mucous membrane are situations that
pose a risk for bloodborne virus transmission and require further evaluation. For HCV
and HIV, exposure to a blood-filled hollow needle or visibly bloody device suggests a
higher risk exposure than exposure to a needle that was most likely used for giving an
injection. In addition, any direct contact (i.e, personal protective equipment either was not
present or was ineffective in protecting skin or mucous membranes) with concentrated
virus in a research laboratory or production facility is considered an exposure that re-
quires clinical evaluation.
For skin exposure, follow-up is indicated only if it involves exposure to a body fluid
previously listed and evidence exists of compromised skin integrity (e.g., dermatitis,
abrasion, or open wound). In the clinical evaluation for human bites, possible exposure of
both the person bitten and the person who inflicted the bite must be considered. If a bite
results in blood exposure to either person involved, postexposure follow-up should be
provided.
BOX 2. Factors to consider in assessing the need for follow-up of occupational
exposures
• Type of exposure
 — Percutaneous injury
 — Mucous membrane exposure
 — Nonintact skin exposure
 — Bites resulting in blood exposure to either person involved
• Type and amount of fluid/tissue
— Blood
— Fluids containing blood
— Potentially infectious fluid or tissue (semen; vaginal secretions; and
cerebrospinal, synovial, pleural, peritoneal, pericardial, and amniotic
fluids)
— Direct contact with concentrated virus
• Infectious status of source
— Presence of HBsAg
— Presence of HCV antibody
— Presence of HIV antibody
• Susceptibility of exposed person
— Hepatitis B vaccine and vaccine response status
— HBV, HCV, and HIV immune status
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Evaluation of the Exposure Source
The person whose blood or body fluid is the source of an occupational exposure
should be evaluated for HBV, HCV, and HIV infection (Box 3). Information available in the
medical record at the time of exposure (e.g., laboratory test results, admitting diagnosis,
or previous medical history) or from the source person, might confirm or exclude
bloodborne virus infection.
If the HBV, HCV, and/or HIV infection status of the source is unknown, the source
person should be informed of the incident and tested for serologic evidence of bloodborne
virus infection. Procedures should be followed for testing source persons, including ob-
taining informed consent, in accordance with applicable state and local laws. Any per-
sons determined to be infected with HBV, HCV, or HIV should be referred for appropriate
counseling and treatment. Confidentiality of the source person should be maintained at
all times.
Testing to determine the HBV, HCV, and HIV infection status of an exposure source
should be performed as soon as possible. Hospitals, clinics and other sites that manage
exposed HCP should consult their laboratories regarding the most appropriate test to
use to expedite obtaining these results. An FDA-approved rapid HIV-antibody test kit
should be considered for use in this situation, particularly if testing by EIA cannot be
completed within 24–48 hours. Repeatedly reactive results by EIA or rapid HIV-antibody
tests are considered to be highly suggestive of infection, whereas a negative result is an
excellent indicator of the absence of HIV antibody. Confirmation of a reactive result by
Western blot or immunofluorescent antibody is not necessary to make initial decisions
about postexposure management but should be done to complete the testing process
and before informing the source person. Repeatedly reactive results by EIA for anti-HCV
should be confirmed by a supplemental test (i.e., recombinant immunoblot assay [RIBA™]
or HCV PCR). Direct virus assays (e.g., HIV p24 antigen EIA or tests for HIV RNA or HCV
RNA) for routine HIV or HCV screening of source persons are not recommended.
If the exposure source is unknown or cannot be tested, information about where and
under what circumstances the exposure occurred should be assessed epidemiologically
for the likelihood of transmission of HBV, HCV, or HIV. Certain situations as well as the
type of exposure might suggest an increased or decreased risk; an important consider-
ation is the prevalence of HBV, HCV, or HIV in the population group (i.e., institution or
community) from which the contaminated source material is derived. For example, an
exposure that occurs in a geographic area where injection-drug use is prevalent or
involves a needle discarded in a drug-treatment facility would be considered epidemio-
logically to have a higher risk for transmission than an exposure that occurs in a nursing
home for the elderly.
Testing of needles or other sharp instruments implicated in an exposure, regardless
of whether the source is known or unknown, is not recommended. The reliability and
interpretation of findings in such circumstances are unknown, and testing might be haz-
ardous to persons handling the sharp instrument.
Examples of information to consider when evaluating an exposure source for pos-
sible HBV, HCV, or HIV infection include laboratory information (e.g., previous HBV, HCV,
or HIV test results or results of immunologic testing [e.g., CD4+ T-cell count]) or liver
enzymes (e.g., ALT), clinical symptoms (e.g., acute syndrome suggestive of primary HIV
infection or undiagnosed immunodeficiency disease), and history of recent (i.e., within 3
months) possible HBV, HCV, or HIV exposures (e.g., injection-drug use or sexual contact
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with a known positive partner). Health-care providers should be aware of local and state
laws governing the collection and release of HIV serostatus information on a source
person, following an occupational exposure.
If the source person is known to have HIV infection, available information about this
person’s stage of infection (i.e., asymptomatic, symptomatic, or AIDS), CD4+ T-cell count,
results of viral load testing, current and previous antiretroviral therapy, and results of
any genotypic or phenotypic viral resistance testing should be gathered for consider-
ation in choosing an appropriate PEP regimen. If this information is not immediately
available, initiation of PEP, if indicated, should not be delayed; changes in the PEP regimen
can be made after PEP has been started, as appropriate. Reevaluation of exposed HCP
should be considered within 72 hours postexposure, especially as additional information
about the exposure or source person becomes available.
If the source person is HIV seronegative and has no clinical evidence of AIDS or
symptoms of HIV infection, no further testing of the person for HIV infection is indicated.
The likelihood of the source person being in the “window period” of HIV infection in the
absence of symptoms of acute retroviral syndrome is extremely small.
BOX 3. Evaluation of occupational exposure sources
Known sources
• Test known sources for HBsAg, anti-HCV, and HIV antibody
— Direct virus assays for routine screening of source patients are
not recommended
— Consider using a rapid HIV-antibody test
— If the source person is not infected with a bloodborne pathogen,
baseline testing or further follow-up of the exposed person is not
necessary
• For sources whose infection status remains unknown (e.g., the
source person refuses testing), consider medical diagnoses,  clinical
symptoms, and history of risk behaviors
• Do not test discarded needles for bloodborne pathogens
Unknown sources
• For unknown sources, evaluate the likelihood of exposure to a source
at  high risk for infection
— Consider likelihood of bloodborne pathogen infection among
patients in the exposure setting
Management of Exposures to HBV
For percutaneous or mucosal exposures to blood, several factors must be considered
when making a decision to provide prophylaxis, including the HBsAg status of the source
and the hepatitis B vaccination and vaccine-response status of the exposed person. Such
exposures usually involve persons for whom hepatitis B vaccination is recommended.
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Any blood or body fluid exposure to an unvaccinated person should lead to initiation of
the hepatitis B vaccine series.
The hepatitis B vaccination status and the vaccine-response status (if known) of the
exposed person should be reviewed. A summary of prophylaxis recommendations for
percutaneous or mucosal exposure to blood according to the HBsAg status of the expo-
sure source and the vaccination and vaccine-response status of the exposed person is
included in this report (Table 3).
When HBIG is indicated, it should be administered as soon as possible after exposure
(preferably within 24 hours). The effectiveness of HBIG when administered >7 days after
exposure is unknown. When hepatitis B vaccine is indicated, it should also be adminis-
tered as soon as possible (preferably within 24 hours) and can be administered simulta-
neously with HBIG at a separate site (vaccine should always be administered in the
deltoid muscle).
For exposed persons who are in the process of being vaccinated but have not com-
pleted the vaccination series, vaccination should be completed as scheduled, and HBIG
should be added as indicated (Table 3). Persons exposed to HBsAg-positive blood or
body fluids who are known not to have responded to a primary vaccine series should
receive a single dose of HBIG and reinitiate the hepatitis B vaccine series with the first
dose of the hepatitis B vaccine as soon as possible after exposure. Alternatively, they
should receive two doses of HBIG, one dose as soon as possible after exposure, and the
second dose 1 month later. The option of administering one dose of HBIG and reinitiating
the vaccine series is preferred for nonresponders who did not complete a second 3-dose
vaccine series. For persons who previously completed a second vaccine series but failed
to respond, two doses of HBIG are preferred.
Management of Exposures to HCV
Individual institutions should establish policies and procedures for testing HCP for
HCV after percutaneous or mucosal exposures to blood and ensure that all personnel are
familiar with these policies and procedures. The following are recommendations for
follow-up of occupational HCV exposures:
• For the source, perform testing for anti-HCV.
• For the person exposed to an HCV-positive source
  — perform baseline testing for anti-HCV and ALT activity; and
  — perform follow-up testing (e.g., at 4–6 months) for anti-HCV and ALT activity (if
earlier diagnosis of HCV infection is desired, testing for HCV RNA may be
performed at 4–6 weeks).
• Confirm all anti-HCV results reported positive by enzyme immunoassay using
supplemental anti-HCV testing (e.g., recombinant immunoblot assay [RIBA™])
(13 ).
Health-care professionals who provide care to persons exposed to HCV in the occu-
pational setting should be knowledgeable regarding the risk for HCV infection and appro-
priate counseling, testing, and medical follow-up.
IG and antiviral agents are not recommended for PEP after exposure to HCV-positive
blood. In addition, no guidelines exist for administration of therapy during the acute
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TABLE 3. Recommended postexposure prophylaxis for exposure to hepatitis B virus
Vaccination Treatment
and antibody Source
response status of Source Source  unknown or not
exposed workers* HBsAg† positive HBsAg† negative available for testing
Unvaccinated HBIG§ x 1 and initiate Initiate HB vaccine Initiate HB vaccine
HB vaccine series¶ series series
Previously vaccinated
Known responder** No treatment No treatment No treatment
Known
nonresponder†† HBIG x 1 and initiate No treatment If known high risk
revaccination source, treat as
or HBIG x 2§§ if source were HBsAg
positive
Antibody response
unknown Test exposed person No treatment Test exposed person
for anti-HBs¶¶ for anti-HBs
1. If adequate,** no 1. If adequate,¶ no
treatment is treatment is
necessary necessary
2. If inadequate,†† 2. If inadequate,¶
administer administer vaccine
HBIG x 1 and booster and
vaccine booster recheck titer in 1–2
months
* Persons who have previously been infected with HBV are immune to reinfection and do not
require postexposure prophylaxis.
† Hepatitis B surface antigen.
§ Hepatitis B immune globulin; dose is 0.06 mL/kg intramuscularly.
¶ Hepatitis B vaccine.
** A responder is a person with adequate levels of serum antibody to HBsAg (i.e., anti-HBs
>10 mIU/mL).
†† A nonresponder is a person with inadequate response to vaccination (i.e., serum anti-HBs
< 10 mIU/mL).
§§ The option of giving one dose of HBIG and reinitiating the vaccine series is preferred for
nonresponders who have not completed a second 3-dose vaccine series. For persons who
previously completed a second vaccine series but failed to respond, two doses of HBIG are
preferred.
¶¶ Antibody to HBsAg.
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phase of HCV infection. However, limited data indicate that antiviral therapy might be
beneficial when started early in the course of HCV infection. When HCV infection is
identified early, the person should be referred for medical management to a specialist
knowledgeable in this area.
Counseling for HCP Exposed to Viral Hepatitis
HCP exposed to HBV- or HCV-infected blood do not need to take any special precau-
tions to prevent secondary transmission during the follow-up period (12,13 ); however,
they should refrain from donating blood, plasma, organs, tissue, or semen. The exposed
person does not need to modify sexual practices or refrain from becoming pregnant. If an
exposed woman is breast feeding, she does not need to discontinue.
No modifications to an exposed person’s patient-care responsibilities are necessary
to prevent transmission to patients based solely on exposure to HBV- or HCV-positive
blood. If an exposed person becomes acutely infected with HBV, the person should be
evaluated according to published recommendations for infected HCP (165 ). No recom-
mendations exist regarding restricting the professional activities of HCP with HCV infec-
tion (13 ). As recommended for all HCP, those who are chronically infected with HBV or
HCV should follow all recommended infection-control practices, including standard pre-
cautions and appropriate use of hand washing, protective barriers, and care in the use
and disposal of needles and other sharp instruments (162 ).
Management of Exposures to HIV
Clinical Evaluation and Baseline Testing of Exposed HCP
HCP exposed to HIV should be evaluated within hours (rather than days) after their
exposure and should be tested for HIV at baseline (i.e., to establish infection status at the
time of exposure). If the source person is seronegative for HIV, baseline testing or further
follow-up of the exposed person normally is not necessary. Serologic testing should be
made available to all HCP who are concerned that they might have been occupationally
infected with HIV. For purposes of considering HIV PEP, the evaluation also should include
information about medications the exposed person might be taking and any current or
underlying medical conditions or circumstances (i.e., pregnancy, breast feeding, or renal
or hepatic disease) that might influence drug selection.
PEP for HIV
The following recommendations (Tables 4 and 5) apply to situations when a person
has been exposed to a source person with HIV infection or when information suggests
the likelihood that the source person is HIV-infected. These recommendations are based
on the risk for HIV infection after different types of exposure and on limited data regard-
ing efficacy and toxicity of PEP. Because most occupational HIV exposures do not result in
the transmission of HIV, potential toxicity must be carefully considered when prescribing
PEP. To assist with the initial management of an HIV exposure, health-care facilities
should have drugs for an initial PEP regimen selected and available for use. When pos-
sible, these recommendations should be implemented in consultation with persons who

















TABLE 4. Recommended HIV postexposure prophylaxis for percutaneous injuries
Infection status of source
Source
HIV-Positive HIV-Positive of unknown
Exposure type Class 1* Class 2*    HIV status† Unknown source§ HIV-Negative
Less severe¶ Recommend basic Recommend Generally, no PEP Generally, no PEP No PEP warranted
2-drug PEP expanded 3-drug warranted; however, warranted; however,
PEP consider basic consider basic
2-drug PEP** for 2-drug PEP** in
source with HIV settings where
risk factors†† exposure to HIV-
infected persons
is likely
More severe§§ Recommend Recommend Generally, no PEP Generally, no PEP No PEP warranted
expanded 3-drug expanded 3-drug warranted; however, warranted; however,
PEP PEP consider basic consider basic
2-drug PEP** for 2-drug PEP** in
source with HIV settings where
risk factors†† exposure to
HIV-infected persons
is likely
* HIV-Positive, Class 1 — asymptomatic HIV infection or known low viral load (e.g., <1,500 RNA copies/mL). HIV-Positive, Class 2 —
symptomatic HIV infection, AIDS, acute seroconversion, or known high viral load. If drug resistance is a concern, obtain expert
consultation. Initiation of postexposure prophylaxis (PEP) should not be delayed pending expert consultation, and, because expert
consultation alone cannot substitute for face-to-face counseling, resources should be available to provide immediate evaluation
and follow-up care for all exposures.
† Source of unknown HIV status (e.g., deceased source person with no samples available for HIV testing).
§ Unknown source (e.g., a needle from a sharps disposal container).
¶ Less severe (e.g., solid needle and superficial injury).
** The designation “consider PEP” indicates that PEP is optional and should be based on an individualized decision between the
exposed person and the treating clinician.
†† If PEP is offered and taken and the source is later determined to be HIV-negative, PEP should be discontinued.


















TABLE 5. Recommended HIV postexposure prophylaxis for mucous membrane exposures and nonintact skin* exposures
Infection status of source
Source
HIV-Positive HIV-Positive of unknown
Exposure type Class 1† Class 2†    HIV status§ Unknown source¶ HIV-Negative
Small volume** Consider basic Recommend basic Generally, no PEP Generally, no PEP No PEP warranted
2-drug PEP†† 2-drug PEP warranted; however, warranted; however,
consider basic consider basic
2-drug PEP†† for 2-drug PEP†† in
source with HIV settings where
risk factors§§ exposure to HIV-
infected persons
is likely
Large volume¶¶ Recommend basic Recommend Generally, no PEP Generally, no PEP No PEP warranted
2-drug PEP expanded 3-drug warranted; however, warranted; however,
PEP consider basic consider basic
2-drug PEP†† for 2-drug PEP†† in
source with HIV settings where
risk factors§§ exposure to
HIV-infected persons
is likely
* For skin exposures, follow-up is indicated only if there is evidence of compromised skin integrity (e.g., dermatitis, abrasion, or open
wound).
† HIV-Positive, Class 1 — asymptomatic HIV infection or known low viral load (e.g., <1,500 RNA copies/mL). HIV-Positive, Class 2 —
symptomatic HIV infection, AIDS, acute seroconversion, or known high viral load. If drug resistance is a concern, obtain expert
consultation.  Initiation of postexposure prophylaxis (PEP) should not be delayed pending expert consultation, and, because expert
consultation alone cannot substitute for face-to-face counseling, resources should be available to provide immediate evaluation
and follow-up care for all exposures.
§ Source of unknown HIV status (e.g., deceased source person with no samples available for HIV testing).
¶ Unknown source (e.g., splash from inappropriately disposed blood).
** Small volume (i.e., a few drops).
†† The designation, “consider PEP,” indicates that PEP is optional and should be based on an individualized decision between the
exposed person and the treating clinician.
§§ If PEP is offered and taken and the source is later determined to be HIV-negative, PEP should be discontinued.
¶¶ Large volume (i.e., major blood splash).
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Timing and Duration of PEP. PEP should be initiated as soon as possible. The interval
within which PEP should be initiated for optimal efficacy is not known. Animal studies
have demonstrated the importance of starting PEP soon after an exposure (111,112,118 ).
If questions exist about which antiretroviral drugs to use or whether to use a basic or
expanded regimen, starting the basic regimen immediately rather than delaying PEP
administration is probably better. Although animal studies suggest that PEP probably is
substantially less effective when started more than 24–36 hours postexposure
(112,119,122 ), the interval after which no benefit is gained from PEP for humans is
undefined. Therefore, if appropriate for the exposure, PEP should be started even when
the interval since exposure exceeds 36 hours. Initiating therapy after a longer interval
(e.g., 1 week) might be considered for exposures that represent an increased risk for
transmission. The optimal duration of PEP is unknown. Because 4 weeks of ZDV ap-
peared protective in occupational and animal studies (100,123 ), PEP probably should be
administered for 4 weeks, if tolerated.
Use of PEP When HIV Infection Status of Source Person is Unknown. If the source
person’s HIV infection status is unknown at the time of exposure, use of PEP should be
decided on a case-by-case basis, after considering the type of exposure and the clinical
and/or epidemiologic likelihood of HIV infection in the source (Tables 4 and 5). If these
considerations suggest a possibility for HIV transmission and HIV testing of the source
person is pending, initiating a two-drug PEP regimen until laboratory results have been
obtained and later modifying or discontinuing the regimen accordingly is reasonable.
The following are recommendations regarding HIV postexposure prophylaxis:
• If indicated, start PEP as soon as possible after an exposure.
• Reevaluation of the exposed person should be considered within 72 hours
postexposure, especially as additional information about the exposure or source
person becomes available.
• Administer PEP for 4 weeks, if tolerated.
• If a source person is determined to be HIV-negative, PEP should be discontinued.
PEP for Pregnant HCP. If the exposed person is pregnant, the evaluation of risk of
infection and need for PEP should be approached as with any other person who has had
an HIV exposure. However, the decision to use any antiretroviral drug during pregnancy
should involve discussion between the woman and her health-care provider(s) regard-
ing the potential benefits and risks to her and her fetus.
Certain drugs should be avoided in pregnant women. Because teratogenic effects
were observed in primate studies, EFV is not recommended during pregnancy. Reports
of fatal lactic acidosis in pregnant women treated with a combination of d4T and ddI have
prompted warnings about these drugs during pregnancy. Because of the risk of hyperbi-
lirubinemia in newborns, IDV should not be administered to pregnant women shortly
before delivery.
Recommendations for the Selection of Drugs for HIV PEP
Health-care providers must strive to balance the risk for infection against the poten-
tial toxicity of the agent(s) used when selecting a drug regimen for HIV PEP. Because PEP
is potentially toxic, its use is not justified for exposures that pose a negligible risk for
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transmission (Tables 4 and 5). Also, insufficient evidence exists to support recommend-
ing a three-drug regimen for all HIV exposures. Therefore, two regimens for PEP are
provided (Appendix C): a “basic” two-drug regimen that should be appropriate for most
HIV exposures and an “expanded” three-drug regimen that should be used for expo-
sures that pose an increased risk for transmission (Tables 4 and 5). When possible, the
regimens should be implemented in consultation with persons who have expertise in
antiretroviral treatment and HIV transmission.
Most HIV exposures will warrant a two-drug regimen using two nucleoside ana-
logues (e.g., ZDV and 3TC; or 3TC and d4T; or d4T and ddI). The addition of a third drug
should be considered for exposures that pose an increased risk for transmission. Selec-
tion of the PEP regimen should consider the comparative risk represented by the expo-
sure and information about the exposure source, including history of and response to
antiretroviral therapy based on clinical response, CD4+ T-cell counts, viral load measure-
ments, and current disease stage. When the source person’s virus is known or suspected
to be resistant to one or more of the drugs considered for the PEP regimen, the selection
of drugs to which the source person’s virus is unlikely to be resistant is recommended;
expert consultation is advised. If this information is not immediately available, initiation
of PEP, if indicated, should not be delayed; changes in the PEP regimen can be made after
PEP has been started, as appropriate. Reevaluation of the exposed person should be
considered within 72 hours postexposure, especially as additional information about the
exposure or source person becomes available.
Follow-up of HCP Exposed to HIV
Postexposure Testing. HCP with occupational exposure to HIV should receive follow-
up counseling, postexposure testing, and medical evaluation, regardless of whether they
receive PEP. HIV-antibody testing should be performed for at least 6 months postexposure
(e.g., at 6 weeks, 12 weeks, and 6 months). Extended HIV follow-up (e.g., for 12 months)
is recommended for HCP who become infected with HCV following exposure to a source
coinfected with HIV and HCV. Whether extended follow-up is indicated in other circum-
stances (e.g., exposure to a source coinfected with HIV and HCV in the absence of HCV
seroconversion or for exposed persons with a medical history suggesting an impaired
ability to develop an antibody response to acute infection) is unclear. Although rare
instances of delayed HIV seroconversion have been reported (167,168 ), the infrequency
of this occurrence does not warrant adding to the anxiety level of the exposed persons
by routinely extending the duration of postexposure follow-up. However, this recom-
mendation should not preclude a decision to extend follow-up in an individual situation
based on the clinical judgement of the exposed person’s health-care provider. HIV testing
should be performed on any exposed person who has an illness that is compatible with
an acute retroviral syndrome, regardless of the interval since exposure. When HIV infec-
tion is identified, the person should be referred to a specialist knowledgeable in the area
of HIV treatment and counseling for medical management.
HIV-antibody testing with EIA should be used to monitor for seroconversion. The
routine use of direct virus assays (e.g., HIV p24 antigen EIA or tests for HIV RNA) to detect
infection in exposed HCP generally is not recommended (169 ). The high rate of false-
positive results of these tests in this setting could lead to unnecessary anxiety and/or
treatment (170,171 ). Despite the ability of direct virus assays to detect HIV infection a
few days earlier than EIA, the infrequency of occupational seroconversion and increased
costs of these tests do not warrant their routine use in this setting.
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• HIV-antibody testing should be performed for at least 6 months postexposure.
• Direct virus assays for routine follow-up of HCP are not recommended.
• HIV testing should be performed on any exposed person who has an illness
compatible with an acute retroviral syndrome.
Monitoring and Management of PEP Toxicity. If PEP is used, HCP should be monitored
for drug toxicity by testing at baseline and again 2 weeks after starting PEP. The scope of
testing should be based on medical conditions in the exposed person and the toxicity of
drugs included in the PEP regimen. Minimally, lab monitoring for toxicity should include a
complete blood count and renal and hepatic function tests. Monitoring for evidence of
hyperglycemia should be included for HCP whose regimens include any PI; if the exposed
person is receiving IDV, monitoring for crystalluria, hematuria, hemolytic anemia, and
hepatitis also should be included. If toxicity is noted, modification of the regimen should
be considered after expert consultation; further diagnostic studies may be indicated.
Exposed HCP who choose to take PEP should be advised of the importance of com-
pleting the prescribed regimen. Information should be provided to HCP about potential
drug interactions and the drugs that should not be taken with PEP, the side effects of the
drugs that have been prescribed, measures to minimize these effects, and the methods
of clinical monitoring for toxicity during the follow-up period. HCP should be advised that
the evaluation of certain symptoms should not be delayed (e.g., rash, fever, back or
abdominal pain, pain on urination or blood in the urine, or symptoms of hyperglycemia
[increased thirst and/or frequent urination]).
HCP who fail to complete the recommended regimen often do so because of the side
effects they experience (e.g., nausea and diarrhea). These symptoms often can be man-
aged with antimotility and antiemetic agents or other medications that target the specific
symptoms without changing the regimen. In other situations, modifying the dose interval
(i.e., administering a lower dose of drug more frequently throughout the day, as recom-
mended by the manufacturer), might facilitate adherence to the regimen. Serious ad-
verse events should be reported to FDA’s MedWatch Program.
Counseling and Education. Although HIV infection following an occupational ex-
posure occurs infrequently, the emotional effect of an exposure often is substantial (172–
174 ). In addition, HCP are given seemingly conflicting information. Although HCP are told
that a low risk exists for HIV transmission, a 4-week regimen of PEP might be recom-
mended, and they are asked to commit to behavioral measures (e.g., sexual abstinence
or condom use) to prevent secondary transmission, all of which influence their lives for
several weeks to months (172 ). Therefore, access to persons who are knowledgeable
about occupational HIV transmission and who can deal with the many concerns an HIV
exposure might generate for the exposed person is an important element of postexposure
management. HIV-exposed HCP should be advised to use the following measures to
prevent secondary transmission during the follow-up period, especially the first 6–12
weeks after the exposure when most HIV-infected persons are expected to seroconvert:
exercise sexual abstinence or use condoms to prevent sexual transmission and to avoid
pregnancy; and refrain from donating blood, plasma, organs, tissue, or semen. If an
exposed woman is breast feeding, she should be counseled about the risk of HIV trans-
mission through breast milk, and discontinuation of breast feeding should be considered,
especially for high-risk exposures. Additionally, NRTIs are known to pass into breast milk,
as is NVP; whether this also is true for the other approved antiretroviral drugs is
unknown.
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The patient-care responsibilities of an exposed person do not need to be modified,
based solely on an HIV exposure, to prevent transmission to patients. If HIV
seroconversion is detected, the person should be evaluated according to published rec-
ommendations for infected HCP (175 ).
Exposed HCP should be advised to seek medical evaluation for any acute illness that
occurs during the follow-up period. Such an illness, particularly if characterized by fever,
rash, myalgia, fatigue, malaise, or lymphadenopathy, might be indicative of acute HIV
infection but also might be indicative of a drug reaction or another medical condition.
For exposures for which PEP is considered appropriate, HCP should be informed that
a) knowledge about the efficacy of drugs used for PEP is limited; b) experts recommend
combination drug regimens because of increased potency and concerns about drug-
resistant virus; c) data regarding toxicity of antiretroviral drugs in persons without HIV
infection or in pregnant women are limited; d) although the short-term toxicity of
antiretroviral drugs is usually limited, serious adverse events have occurred in persons
taking PEP; and e) any or all drugs for PEP may be declined or stopped by the exposed
person. HCP who experience HIV occupational exposures for which PEP is not recom-
mended should be informed that the potential side effects and toxicity of taking PEP
outweigh the negligible risk of transmission posed by the type of exposure.
Guidelines for counseling and educating HCP with HIV exposure include
• Exposed HCP should be advised to use precautions to prevent secondary
transmission during the follow-up period.
• For exposures for which PEP is prescribed, HCP should be informed about possible
drug toxicities and the need for monitoring, and possible drug interactions.
Occupational Exposure Management Resources
Several resources are available that provide guidance to HCP regarding the manage-
ment of occupational exposures. These resources include PEPline; the Needlestick!
website; the Hepatitis Hotline; CDC (receives reports of occupationally acquired HIV
infections and failures of PEP); the HIV Antiretroviral Pregnancy Registry; FDA (receives
reports of unusual or severe toxicity to antiretroviral agents); and the HIV/AIDS Treat-
ment Information Service (Box 5).
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• Delayed (i.e., later than 24–36 hours) exposure report
— the interval after which there is no benefit from postexposure
prophylaxis (PEP) is undefined
• Unknown source (e.g., needle in sharps disposal container or laundry)
— decide use of PEP on a case-by-case basis
— consider the severity of the exposure and the epidemiologic
likelihood of HIV exposure
— do not test needles or other sharp instruments for HIV
• Known or suspected pregnancy in the exposed person
— does not preclude the use of optimal PEP regimens
— do not deny PEP solely on the basis of pregnancy
• Resistance of the source virus to antiretroviral agents
— influence of drug resistance on transmission risk is unknown
— selection of drugs to which the source person’s virus is unlikely to be
resistant is recommended, if the source person’s virus is known or
suspected to be resistant to >1 of the drugs considered for the PEP
regimen
— resistance testing of the source person’s virus at the time of the
exposure is not  recommended
• Toxicity of the initial PEP regimen
— adverse symptoms, such as nausea and diarrhea are common
with PEP
— symptoms often can be managed without changing the PEP regimen
by prescribing antimotility and/or antiemetic agents
— modification of dose intervals (i.e., administering a lower dose of drug
more frequently throughout the day, as recommended by the
manufacturer), in other situations, might help alleviate symptoms
*Local experts and/or the National Clinicians’ Post-Exposure Prophylaxis Hotline (PEPline
[1-888-448-4911]).
BOX 4. Situations for which expert* consultation for HIV postexposure prophylaxis
is advised
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National Clinicians’ Postexposure
Prophylaxis Hotline (PEPline)
Run by University of California–
San Francisco/San Francisco
General Hospital staff; supported
by the Health Resources and
Services Administration Ryan
White CARE Act, HIV/AIDS
Bureau, AIDS Education and
Training Centers, and CDC.
Needlestick!
A website to help clinicians
manage and document occupa-
tional blood and body fluid
exposures. Developed and
maintained by the University of
California, Los Angeles (UCLA),
Emergency Medicine Center,
UCLA School of Medicine, and
funded in party by CDC and the
Agency for Healthcare Research
and Quality.
Hepatitis Hotline.
Reporting to CDC: Occupationally




















BOX 5. Occupational exposure management resources
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Food and Drug Administration













BOX 5. (Continued ) Occupational exposure management resources
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APPENDIX A.
Practice Recommendations for Health-Care Facilities
Implementing the U.S. Public Health Service Guidelines
for Management of Occupational Exposures
to Bloodborne Pathogens
Practice recommendation Implementation checklist
Establish a bloodborne All institutions where health-care personnel (HCP)
pathogen policy. might experience exposures should have a written
policy for management of exposures.
The policy should be based on the U.S. Public
Health Service (PHS) guidelines.
The policy should be reviewed periodically
to ensure that it is consistent with PHS
recommendations.
Implement management policies. Health-care facilities (HCF) should provide
appropriate training to all personnel on the
prevention of and response to occupational
exposures.
HCF should establish hepatitis B vaccination
programs.
HCF should establish exposure-reporting systems.
HCF should have personnel who can manage an
exposure readily available at all hours of the day.
HCF should have ready access to postexposure
prophylaxis (PEP) for use by exposed personnel as
necessary.
Establish laboratory capacity HCF should provide prompt processing of exposed
for bloodborne pathogen testing. person and source person specimens to guide
management of occupational exposures.
Testing should be performed with appropriate
counseling and consent.
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Select and use appropriate HCF should develop a policy for the selection and use
PEP regimens. of PEP antiretroviral regimens for HIV exposures
within their institution.
Hepatitis B vaccine and HBIG should be available for
timely administration.
HCF should have access to resources with expertise
in the selection and use of PEP.
Provide access to counseling HCF should provide counseling for HCP who might
for exposed HCP. need help dealing with the emotional effect of an
exposure.
HCF should provide medication adherence counsel-
ing to assist HCP in completing HIV PEP as necessary.
Monitor for adverse effects HCP taking antiretroviral PEP should be monitored
of PEP. periodically for adverse effects of PEP through
baseline and testing (every 2 weeks) and clinical
evaluation.
Monitor for seroconversion. HCF should develop a system to encourage exposed
HCP to return for follow-up testing.
Exposed HCP should be tested for HCV and HIV.
Monitor exposure HCF should develop a system to monitor reporting
management programs. and management of occupational exposures to
ensure timely and appropriate response.
Evaluate
• exposure reports for completeness and accuracy,
• access to care (i.e., the time of exposure to the
time of evaluation), and
• laboratory result reporting time.
Review
• exposures to ensure that HCP exposed to sources
not infected with bloodborne pathogens do not
receive PEP or that PEP is stopped.
Monitor
• completion rates of HBV vaccination and HIV PEP
and
• completion of exposure follow-up.
Practice recommendation Implementation checklist
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APPENDIX B.
Management of Occupational Blood Exposures
Provide immediate care to the exposure site.
• Wash wounds and skin with soap and water.
• Flush mucous membranes with water.
Determine risk associated with exposure by
• type of fluid (e.g., blood, visibly bloody fluid, other potentially infectious fluid or
tissue, and concentrated virus) and
• type of exposure (i.e., percutaneous injury, mucous membrane or nonintact skin
exposure, and bites resulting in blood exposure).
Evaluate exposure source.
• Assess the risk of infection using available information.
• Test known sources for HBsAg, anti-HCV, and HIV antibody (consider using rapid
testing).
• For unknown sources, assess risk of exposure to HBV, HCV, or HIV infection.
• Do not test discarded needles or syringes for virus contamination.
Evaluate the exposed person.
• Assess immune status for HBV infection (i.e., by history of hepatitis B vaccination
and vaccine response).
Give PEP for exposures posing risk of infection transmission.
• HBV: See Table 3.
• HCV: PEP not recommended.
• HIV: See Tables 4 and 5.
— Initiate PEP as soon as possible, preferably within hours of exposure.
— Offer pregnancy testing to all women of childbearing age not known to be
pregnant.
— Seek expert consultation if viral resistance is suspected.
— Administer PEP for 4 weeks if tolerated.
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Perform follow-up testing and provide counseling.
• Advise exposed persons to seek medical evaluation for any acute illness occurring
during follow-up.
HBV exposures
• Perform follow-up anti-HBs testing in persons who receive hepatitis B vaccine.
— Test for anti-HBs 1–2 months after last dose of vaccine.
— Anti-HBs response to vaccine cannot be ascertained if HBIG was
received in the previous 3–4 months.
HCV exposures
• Perform baseline and follow-up testing for anti-HCV and alanine amino-
transferase (ALT) 4–6 months after exposures.
• Perform HCV RNA at 4–6 weeks if earlier diagnosis of HCV infection desired.
• Confirm repeatedly reactive anti-HCV enzyme immunoassays (EIAs) with
supplemental tests.
HIV exposures
• Perform HIV-antibody testing for at least 6 months postexposure (e.g., at
baseline,  6 weeks, 3 months, and 6 months).
• Perform HIV antibody testing if illness compatible with an acute retroviral
syndrome occurs.
• Advise exposed persons to use precautions to prevent secondary
transmission  during the follow-up period.
• Evaluate exposed persons taking PEP within 72 hours after exposure and
monitor for drug toxicity for at least 2 weeks.
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APPENDIX C.
Basic and Expanded HIV Postexposure
Prophylaxis Regimens
BASIC REGIMEN
• Zidovudine (RETROVIR™; ZDV; AZT) + Lamivudine (EPIVIR™; 3TC);
available as COMBIVIR™
— ZDV: 600 mg per day, in two or three divided doses, and
— 3TC: 150 mg twice daily.
Advantages
— ZDV is associated with decreased risk of HIV transmission in the CDC case-
control study of occupational HIV infection.
— ZDV has been used more than the other drugs for PEP in HCP.
— Serious toxicity is rare when used for PEP.
— Side effects are predictable and manageable with antimotility and antiemetic
agents.
— Probably a safe regimen for pregnant HCP.
— Can be given as a single tablet (COMBIVIR™) twice daily.
Disadvantages
— Side effects are common and might result in low adherence.
— Source patient virus might have resistance to this regimen.
—  Potential for delayed toxicity (oncogenic/teratogenic) is unknown.
ALTERNATE BASIC REGIMENS
• Lamivudine (3TC) + Stavudine (ZERIT™; d4T)
— 3TC: 150 mg twice daily, and
— d4T: 40 mg (if body weight is <60 kg, 30 mg twice daily) twice daily.
Advantages
— well tolerated in patients with HIV infection, resulting in good adherence,
— serious toxicity appears to be rare, and
— twice daily dosing might improve adherence.
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Disadvantages
— Source patient virus might be resistant to this regimen.
— Potential for delayed toxicity (oncogenic/teratogenic) is unknown.
• Didanosine (VIDEX™, chewable/dispersable buffered tablet; VIDEX™ EC,
delayed-release capsule; ddI) + Stavudine (d4T)
— ddI: 400 mg (if body weight is <60 kg, 125 mg twice daily) daily, on an empty
stomach.
— d4T: 40 mg (if body weight is <60 kg, 30 mg twice daily) twice daily.
Advantages
— Likely to be effective against HIV strains from source patients who are taking
ZDV and 3TC.
Disadvantages
— ddl is difficult to administer and unpalatable.
— Chewable/dispersable buffered tablet formulation of ddI interferes with
absorption of some drugs (e.g., quinolone antibiotics, and indinavir).
— Serious toxicity (e.g., neuropathy, pancreatitis, or hepatitis) can occur. Fatal
and nonfatal pancreatitis has occurred in HIV-positive, treatment-naive patients.
Patients taking ddI and d4T should be  carefully assessed and closely monitored
for pancreatitis, lactic acidosis, and hepatitis.
— Side effects are common; anticipate diarrhea and low adherence.
— Potential for delayed toxicity (oncogenic/teratogenic) is unknown.
EXPANDED REGIMEN
Basic regimen plus one of the following:
• Indinavir (CRIXIVAN™; IDV)
— 800 mg every 8 hours, on an empty stomach.
Advantages
— Potent HIV inhibitor.
Disadvantages
— Serious toxicity (e.g., nephrolithiasis) can occur; must take 8 glasses of fluid per
day.
— Hyperbilirubinemia common; must avoid this drug during late pregnancy.
Vol. 50 / No. RR-11 MMWR 49
— Requires acid for absorption and cannot be taken simultaneously with ddI in
chewable/dispersable buffered tablet formulation (doses must be separated
by at least 1 hour).
— Concomitant use of astemizole, terfenadine, dihydroergotamine, ergotamine,
ergonovine, methylergonovine, rifampin, cisapride, St. John’s Wort, lovastatin,
simvastatin, pimozide, midazolam, or triazolam is not recommended.
— Potential for delayed toxicity (oncogenic/teratogenic) is unknown.
• Nelfinavir (VIRACEPT™; NFV)
— 750 mg three times daily, with meals or snack, or
— 1250 mg twice daily, with meals or snack.
Advantages
— potent HIV inhibitor, and
— twice dosing per day might improve adherence.
Disadvantages
—  Concomitant use of astemizole, terfenadine, dihydroergotamine, ergotamine,
ergonovine, methylergonovine, rifampin, cisapride, St. John’s Wort, lovastatin,
simvastatin, pimozide, midazolam, or triazolam is not recommended.
— Might accelerate the clearance of certain drugs, including oral  contraceptives
(requiring alternative or additional contraceptive measures for women taking
these drugs).
— Potential for delayed toxicity (oncogenic/teratogenic) is unknown.
• Efavirenz (SUSTIVA™; EFV)
— 600 mg daily, at bedtime.
Advantages
— Does not require phosphorylation before activation and might be active earlier
than other antiretroviral agents (note: this might be only a theoretical
advantage of no clinical benefit.)
— One dose daily might improve adherence.
Disadvantages
— Drug is associated with rash (early onset) that can be severe and might rarely
progress to Stevens-Johnson syndrome.
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— Differentiating between early drug-associated rash and acute seroconversion
can be difficult and cause extraordinary concern for the exposed person.
— Nervous system side effects (e.g., dizziness, somnolence, insomnia, and/or
abnormal dreaming) are common. Severe psychiatric symptoms are possible
(dosing before bedtime might minimize these side effects).
— Should not be used during pregnancy because of concerns about teratogenicity.
— Concomitant use of astemizole, cisapride, midazolam, triazolam, ergot
derivatives, or St. John’s Wort is not recommended because inhibition of the
metabolism of these drugs could create the potential for serious and/or life-
threatening adverse events (e.g., cardiac arrhythmias, prolonged sedation, or
respiratory depression).
— Potential for oncogenic toxicity is unknown.
• Abacavir (ZIAGEN™; ABC); available as TRIZIVIR™, a combination of ZDV, 3TC,
and ABC
— 300 mg twice daily.
Advantages
— potent HIV inhibitor, and
— well tolerated in patients with HIV infection.
Disadvantages
— Severe hypersensitivity reactions can occur, usually within the first 6 weeks
of treatment.
— Potential for delayed toxicity (oncogenic/teratogenic) is unknown.
ANTIRETROVIRAL AGENTS FOR USE AS PEP ONLY WITH EXPERT CONSULTATION
• Ritonavir (NORVIR™; RTV)
Disadvantages
— difficult to take (requires dose escalation),
— poor tolerability, and
— many drug interactions.
• Saquinavir (FORTOVASE™, soft-gel formulation; SQV)
Disadvantages
— Bioavailability is relatively poor, even with new formulation.
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• Amprenavir (AGENERASE™; AMP)
Disadvantages
— Dosage consists of eight large pills taken twice daily.
— Many drug interactions.
• Delavirdine (RESCRIPTOR™; DLV)
Disadvantages
— Drug is associated with rash (early onset) that can be severe and progress to
Stevens-Johnson syndrome.
— Many drug interactions.
• Lopinavir/Ritonavir (KALETRA™)
— 400/100 mg twice daily.
Advantages
— potent HIV inhibitor, and
— well tolerated in patients with HIV infection.
Disadvantages
— Concomitant use of flecainide, propafenone, astemizole, terfenadine,
dihydroergotamine, ergotamine, ergonovine, methylergonovine, rifampin,
cisapride, St. John’s Wort, lovastatin, simvastatin, pimozide, midazolam, or
triazolam is not recommended because inhibition of the metabolism of these
drugs could create the potential for serious and/or life-threatening adverse
events (e.g., cardiac arrhythmias, prolonged sedation, or respiratory
depression).
 — May accelerate the clearance of certain drugs, including oral contraceptives
(requiring alternative or additional contraceptive measures for women taking
these drugs).
— Potential for delayed toxicity (oncogenic/teratogenic) is unknown.
ANTIRETROVIRAL AGENTS GENERALLY NOT RECOMMENDED FOR USE AS PEP
• Nevirapine (VIRAMUNE™; NVP)
—  200 mg daily for 2 weeks, then 200 mg twice daily.
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Disadvantages
— Associated with severe hepatotoxicity (including at least one case of liver
failure requiring liver transplantation in an exposed person taking PEP),
— Associated with rash (early onset) that can be severe and progress to Stevens-
Johnson syndrome,
— Differentiating between early drug-associated rash and acute seroconversion
can be difficult and cause extraordinary concern for the exposed person, and
— Concomitant use of St. John’s Wort is not recommended because this might
result in suboptimal antiretroviral drug concentrations.
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GOALS and OBJECTIVES:
The MMWR provides recommendations regarding the guidance of clinical practice and policy development related
to the management of occupational exposures to blood and bloodborne pathogens, including the appropriate use of
postexposure prophylaxis (PEP). Upon completion of this educational activity, the reader should be able to
a) describe the management process following an occupational exposure to blood; b) describe the evaluation of the
exposure and assessment of the risk for bloodborne pathogen transmission; c) describe appropriate laboratory
evaluation of the exposed worker and source person; d) describe appropriate selection and use of PEP; and
e) describe the follow-up evaluation and counseling of exposed health-care personnel (HCP).
To receive continuing education credit, please answer all of the following questions.
1. Factors to consider in assessing the need for follow-up after an occupational exposure
include
A. The type of exposure.
B. The type of fluid.
C. The bloodborne pathogen infection status of the source.
D. The susceptibility of the exposed.
E. All of the above.
F. None of the above.
2. Which of the following exposures pose a risk for bloodborne pathogen infection?
A. A nurse sustains a needlestick while drawing up insulin to administer to a patient
with diabetes.
B. A lab worker is splashed in the eye with urine from a patient with HIV.
C. An operating room technician with chapped and abraded hands notices blood
under his/her gloves after assisting in a surgery on a patient with hepatitis C
infection.
D. While cleaning the bathroom, a housekeeper’s intact skin has contact with feces.
3. Which lab tests should be completed for the exposed person to determine his/her
susceptibility to a bloodborne pathogen infection?
A. HBsAg.
B. HIV p24 antigen.
C. HCV RNA.
D. All of the above.
E. None of the above.
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4. Following a percutaneous exposure to HCV-infected blood, what action(s) is/are
recommended?
A. Test the exposed person for antibody to HCV and alanine aminotransferase (ALT) at
the time of the exposure and 4–6 months postexposure.
B. Administer one dose of immune globulin within 7 days of the exposure.
C. Immediately start PEP with interferon and ribavirin.
D. All of the above.
E. None of the above.
5. After completing the initial 3-dose vaccine series against HBV, HCP who will have
contact with patients or blood and are at ongoing risk for percutaneous injuries should
have anti-HBs testing completed
A. Every year.
B. After any blood exposure.
C. 1–2 months after the completion of the vaccine series.
D. All of the above.
E. None of the above.
6. The type of occupational exposure to HIV-infected blood that poses the greatest risk  for
infection transmission is
A. A percutaneous injury.
B. A mucous membrane exposure.
C. A bite.
D. Skin contact with HIV-infected blood.
7. For which of the following exposures would the use of HIV PEP be recommended?
A. A housekeeper sustains a percutaneous injury while emptying a needle box on a
pediatric ward with no known cases of HIV infection.
B. A nurse has a urine splash to the eye while emptying an AIDS patient’s urinal.
C. A resident, after assisting with an emergency insertion of a central venous line into
an HIV-infected patient, notices a small tear in his/her glove but does not observe
any blood on his/her skin.
D. A phlebotomist sustains a percutaneous injury while performing phlebotomy on an
HIV-infected patient.
E. All of the above.
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8. Following an exposure to a bloodborne pathogen, what information would be included
as part of the postexposure counseling? (Indicate all that apply.)
A. HCP exposed to HBV and HCV do not need to take any special precautions to
prevent secondary transmission during the follow-up period.
B. Modifying an exposed person’s patient care responsibilities is not necessary to
prevent transmission to patients after an exposure to HBV, HCV, or HIV.
C. HCP who have an HIV exposure for which PEP is not recommended should be
informed that the potential side effects and toxicity of taking  PEP outweigh the risk
of transmission posed by the type of exposure.
D. HCP should seek medical evaluation for any acute illness that occurs during the
follow-up period.
9. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.
10. Which best describes your professional activities?
A. Patient care—emergency/urgent care department.
B. Patient care—inpatient.




11. I plan to use these recommendations as the basis for ... (Indicate all that apply.)
A. Health-education materials.
B. Insurance reimbursement policies.
C. Local practice guidelines.
D. Public policy.
E. Other.








Vol. 50 / No. RR-11 MMWR CE–5
13. How much time did you spend reading this report and completing the exam?
A. 1–1.5 hours.
B. More than 1.5 hours but fewer than 2 hours.
C. 2–2.5 hours.
D. More than 2.5 hours.
14. After reading this report, I am confident that I can describe the management process
following an occupational exposure to blood.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
15. After reading this report, I am confident that I can describe the evaluation of the
exposure and assessment of the risk for bloodborne pathogen transmission.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
16. After reading this report, I am confident that I can describe appropriate laboratory
evaluation of the exposed worker and source person.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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18. After this report, I am confident that I can describe the follow-up evaluation and
counseling of an exposed worker.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
19. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
20. The tables, boxes, and appendices are useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. Overall, the presentation of the report enhanced my ability to understand the material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
23. How did you learn about this continuing education activity?
A. Internet.





Correct answers for questions 1–8.
1. E; 2. C; 3. E; 4. A; 5. C; 6. A; 7. D; 8. A, B, C, D.
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